Oncimmune (LON:ONC) Trading Down 4.2% – Should You Sell?

Shares of Oncimmune Holdings plc (LON:ONCGet Free Report) fell 4.2% during trading on Monday . The stock traded as low as GBX 14.85 ($0.19) and last traded at GBX 14.85 ($0.19). 210,591 shares changed hands during trading, an increase of 72% from the average session volume of 122,679 shares. The stock had previously closed at GBX 15.50 ($0.20).

Oncimmune Stock Down 4.2 %

The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 806.85. The firm has a market capitalization of £11.01 million, a price-to-earnings ratio of -495.00 and a beta of 1.19. The stock has a 50 day moving average of GBX 16.76 and a 200 day moving average of GBX 16.33.

Oncimmune Company Profile

(Get Free Report)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Featured Articles

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.